We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$38.6M
Cap. Flow
+$20.8M
Cap. Flow %
3.22%
Top 10 Hldgs %
64.44%
Holding
59
New
19
Increased
16
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$29.4M
2
TSRO
TESARO, Inc.
TSRO
+$21.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
ESPR
Esperion Therapeutics
ESPR
+$14.5M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$8.94M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$21.7M
3
SHPG
Shire pic
SHPG
+$20.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$14.9M
5
CORT icon
Corcept Therapeutics
CORT
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 60.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
51
Larimar Therapeutics
LRMR
$377M
– –
-33,463
Closed -$2.99M
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-36,226
Closed -$4.23M
PRGO icon
53
Perrigo
PRGO
$1.43B
– –
-55,748
Closed -$4.65M
VYNE icon
54
VYNE Therapeutics
VYNE
– –
-21
Closed -$2.79M
XENE icon
55
Xenon Pharmaceuticals
XENE
$6.16B
– –
-379,071
Closed -$1.86M
QTTB icon
56
Q32 Bio
QTTB
$449M
– –
-722
Closed -$243K
LUMO
57
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-55,556
Closed -$3.63M
CLVS
58
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-242,600
Closed -$12.8M
SHPG
59
DELISTED
Shire pic
SHPG
– –
-139,543
Closed -$20.8M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Nexthera Capital held 59 positions worth $646M, up 6.4% from $607M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nexthera Capital deployed $20.8M of net new capital in Q2 2018, opening 19 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,421,600 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $14.9M trimmed.

  • Nexthera Capital's largest Q2 2018 buy was Exelixis: 1,421,600 shares worth $30.6M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q2 2018, an estimated $6.87M increase.
  • Nexthera Capital's biggest Q2 2018 reduction was Seagen Inc. Common Stock, cutting an estimated $14.9M.
  • Nexthera Capital fully exited BioMarin Pharmaceuticals in Q2 2018, selling an estimated $22.7M.
  • Nexthera Capital's ten largest holdings make up 64% of its $646M portfolio in Q2 2018.
  • Nexthera Capital opened 19 new positions and closed 14 in Q2 2018.
  • Nexthera Capital's portfolio value rose 6.4% quarter-over-quarter to $646M.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.